Anti-Ebola therapies based on monoclonal antibodies: current state and challenges ahead

Everardo González-GonzálezCentro de Biotecnología-FEMSA, Tecnológico de Monterrey, Monterrey, Nuevo León, Mexico,

Mario Moisés AlvarezCentro de Biotecnología-FEMSA, Tecnológico de Monterrey, Monterrey, Nuevo León, Mexico, ;Biomaterials Innovation Research Center, Division of Biomedical Engineering, Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA, ;Division of Health Sciences and Technology, Massachusetts Institute of Technology, Cambridge, MA, USA, ;Microsystems Technologies Laboratories, Massachusetts Institute of Technology, Cambridge, MA, USA, Correspondence[email protected] [email protected]

Alan Roberto Márquez-IpiñaCentro de Biotecnología-FEMSA, Tecnológico de Monterrey, Monterrey, Nuevo León, Mexico,

Grissel Trujillo-de SantiagoCentro de Biotecnología-FEMSA, Tecnológico de Monterrey, Monterrey, Nuevo León, Mexico, ;Biomaterials Innovation Research Center, Division of Biomedical Engineering, Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA, ;Division of Health Sciences and Technology, Massachusetts Institute of Technology, Cambridge, MA, USA, ;Microsystems Technologies Laboratories, Massachusetts Institute of Technology, Cambridge, MA, USA,

Luis Mario Rodríguez-MartínezCentro de Biotecnología-FEMSA, Tecnológico de Monterrey, Monterrey, Nuevo León, Mexico,

Nasim AnnabiBiomaterials Innovation Research Center, Division of Biomedical Engineering, Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA, ;Division of Health Sciences and Technology, Massachusetts Institute of Technology, Cambridge, MA, USA, ;Department of Chemical Engineering, Northeastern University, Boston, MA, USA,

Ali KhademhosseiniBiomaterials Innovation Research Center, Division of Biomedical Engineering, Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA, ;Division of Health Sciences and Technology, Massachusetts Institute of Technology, Cambridge, MA, USA, ;Microsystems Technologies Laboratories, Massachusetts Institute of Technology, Cambridge, MA, USA, ;Wyss Institute for Biologically Inspired Engineering, Harvard University, Boston, MA, USA, ;Department of Physics, King Abdulaziz University, Jeddah, Saudi Arabia, and ;Department of Bioindustrial Technologies, College of Animal Bioscience and Technology, Konkuk University, Hwayang-dong, Gwangjin-gu, Seoul, Republic of Korea

show all

Anti-Ebola therapies based on monoclonal antibodies: current state and challenges ahead

Articles from other publishers (13)

Information for

Open access

Opportunities

Help and information

Your download is now in progress and you may close this window

Login or register to access this feature

Anti-Ebola therapies based on monoclonal antibodies: current state and challenges ahead

Citations (16)

Read on this site (3)

Articles from other publishers (13)

Reprints and Corporate Permissions

Academic Permissions

Related research

To cite this article:

Download citation

Information for

Open access

Opportunities

Help and information

Keep up to date